Copper complexes as therapeutic agents
- PMID: 22187112
- DOI: 10.1039/c2mt00174h
Copper complexes as therapeutic agents
Abstract
The importance of transition metals in biological processes has been well established. Copper (Cu) is a transition metal that can exist in oxidised and reduced states. This allows it to participate in redox and catalytic chemistry, making it a suitable cofactor for a diverse range of enzymes and molecules. Cu deficiency or toxicity is implicated in a variety of pathological conditions; therefore inorganic complexes of Cu have been investigated for their therapeutic and diagnostic potential. These Cu complexes have been shown to be effective in cancer treatment due to their cytotoxic action on tumour cells. Alternatively, Cu complexes can also modulate Cu homeostasis in the brain, resulting in protective effects in several models of neurodegeneration. In other diseases such as coronary heart disease and skin disease, the success of Cu complexes as potential therapeutics will most likely be due to their ability to increase SOD activity, leading to relief of oxidative stress. This review seeks to provide a broad insight into some of the diverse actions of Cu complexes and demonstrate the strong future for these compounds as potential therapeutic agents.
Similar articles
-
Nitroimidazole and glucosamine conjugated heteroscorpionate ligands and related copper(II) complexes. Syntheses, biological activity and XAS studies.Dalton Trans. 2011 Oct 14;40(38):9877-88. doi: 10.1039/c1dt10486a. Epub 2011 Jun 28. Dalton Trans. 2011. PMID: 21709917
-
Mechanisms controlling the cellular accumulation of copper bis(thiosemicarbazonato) complexes.Inorg Chem. 2011 Oct 3;50(19):9594-605. doi: 10.1021/ic201334q. Epub 2011 Sep 1. Inorg Chem. 2011. PMID: 21882803
-
Copper, gold and silver compounds as potential new anti-tumor metallodrugs.Future Med Chem. 2010 Oct;2(10):1591-608. doi: 10.4155/fmc.10.234. Future Med Chem. 2010. PMID: 21426151 Review.
-
Complex formation, thermal behavior and stability competition between Cu(II) ion and Cu(0) nanoparticles with some new azo dyes. Antioxidant and in vitro cytotoxic activity.Spectrochim Acta A Mol Biomol Spectrosc. 2013 Apr 15;107:359-70. doi: 10.1016/j.saa.2013.01.039. Epub 2013 Jan 31. Spectrochim Acta A Mol Biomol Spectrosc. 2013. PMID: 23434564
-
Novel copper complexes as potential proteasome inhibitors for cancer treatment (Review).Mol Med Rep. 2017 Jan;15(1):3-11. doi: 10.3892/mmr.2016.6022. Epub 2016 Dec 9. Mol Med Rep. 2017. PMID: 27959411 Review.
Cited by
-
Gold(I) NHC-based homo- and heterobimetallic complexes: synthesis, characterization and evaluation as potential anticancer agents.J Biol Inorg Chem. 2015 Sep;20(6):1005-20. doi: 10.1007/s00775-015-1283-1. Epub 2015 Jul 23. J Biol Inorg Chem. 2015. PMID: 26202908
-
Copper and anesthesia: clinical relevance and management of copper related disorders.Anesthesiol Res Pract. 2013;2013:750901. doi: 10.1155/2013/750901. Epub 2013 May 13. Anesthesiol Res Pract. 2013. PMID: 23762044 Free PMC article.
-
Copper signalling: causes and consequences.Cell Commun Signal. 2018 Oct 22;16(1):71. doi: 10.1186/s12964-018-0277-3. Cell Commun Signal. 2018. PMID: 30348177 Free PMC article. Review.
-
Coordination Compounds of Cu, Zn, and Ni with Dicarboxylic Acids and N Donor Ligands, and Their Biological Activity: A Review.Molecules. 2023 Feb 2;28(3):1445. doi: 10.3390/molecules28031445. Molecules. 2023. PMID: 36771123 Free PMC article. Review.
-
Downregulation of oncogenic RAS and c-Myc expression in MOLT-4 leukaemia cells by a salicylaldehyde semicarbazone copper(II) complex.Sci Rep. 2016 Nov 14;6:36868. doi: 10.1038/srep36868. Sci Rep. 2016. PMID: 27841290 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical